IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY

被引：0

作者：

Roberts, Stuart K. ^{[1
]}

Andreone, Pietro ^{[2
]}

Pol, Stanislas ^{[3
,4
]}

Younossi, Zobair M. ^{[5
,6
]}

Diago, Moises ^{[7
]}

Lawitz, Eric ^{[8
]}

Focaccia, Roberto ^{[9
]}

Foster, Graham R. ^{[10
]}

Horban, Andrzej ^{[11
]}

Lonjon-Domanec, Isabelle ^{[12
]}

DeMasi, Ralph ^{[13
]}

van Heeswijk, Rolf ^{[14
]}

Picchio, Gaston ^{[13
]}

Witek, James ^{[13
]}

Zeuzem, Stefan ^{[15
]}

机构：

[1] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[2] Univ Bologna, Bologna, Italy

[3] Univ Paris 05, INSERM, U1016, Paris, France

[4] Cochin Hosp, Assistance Publ Hop Paris, Paris, France

[5] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA

[6] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA

[7] Hosp Gen Valencia, Valencia, Spain

[8] Alamo Med Res, San Antonio, TX USA

[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil

[10] Queen Marys Univ London, Inst Cell & Mol Sci, London, England

[11] Med Univ Warsaw, Warsaw, Poland

[12] Janssen Pharmaceut, Paris, France

[13] Tibotec Inc, Titusville, NJ USA

[14] Tibotec BVBA, Beerse, Belgium

[15] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany

来源：

HEPATOLOGY | 2011年 / 54卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1007A / 1008A

页数：2

共 50 条

[31] Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
Christensen, Stefan
Gillessen, Anton
INFECTIOUS AGENTS AND CANCER, 2014, 9
[32] Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
Stefan Christensen
Anton Gillessen
Infectious Agents and Cancer, 9
[33] Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease
Zeuzem, Stefan
DeMasi, Ralph
Foster, Graham R.
Buti, Maria
Laeuffer, Joerg M.
Luo, Donghan
Witek, James
Rizzetto, Mario
HEPATOLOGY, 2013, 58 : 1129A - 1129A
[34] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials
Kieffer, T. L.
De Meyer, S.
Bartels, D. J.
Sullivan, J. C.
Dierynck, I.
Adda, N.
Kwong, A.
Jacobson, I. M.
Sherman, K. E.
Zeuzem, S.
Picchio, G.
ANTIVIRAL THERAPY, 2011, 16 : A27 - A27
[35] Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study
Fevery, B.
Verbinnen, T.
Peeters, M.
Janssen, K.
Witek, J.
Jessner, W.
De Meyer, S.
Lenz, O.
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (01) : 28 - 36
[36] TELAPREVIR- BASED THERAPY IN G1 HCV-INFECTED PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN: REALIZE TRIAL FINAL RESULTS
Foster, G.
Zeuzem, S.
Andreone, P.
Pol, S.
Lawitz, E.
Diago, M.
Roberts, S.
Focaccia, R.
Younossi, Z.
H, A.
Heeswijk, R. V.
de Meyer, S.
Luo, D.
Picchio, G.
Beumont, M.
GUT, 2011, 60 : A50 - A51
[37] Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
Chung, Woo Jin
CLINICAL AND MOLECULAR HEPATOLOGY, 2012, 18 (03) : 268 - 271
[38] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
Vijgen, Leen
Dierynck, Inge
Janssen, Katrien
Talloen, Willem
Gys, Luc
Vanhoof, Greet
Luo, Donghan
De Meyer, Sandra
Witek, James
Aerssens, Jeroen
HEPATOLOGY, 2013, 58 : 1096A - 1097A
[39] BASELINE VITAMIN D LEVELS DO NOT INFLUENCE SVR IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION UNDERGOING PEGINTERFERON/RIBAVIRIN TREATMENT
Stauber, R. E.
Scherzer, T.
Putz-Bankuti, C.
Matejka, J.
Spindelboeck, W.
Zinober, K.
Beinhardt, S.
Wehr, E.
Stojakovic, T.
Kessler, H. H.
Ferenci, P.
Obermayer-Pietsch, B.
JOURNAL OF HEPATOLOGY, 2011, 54 : S468 - S469
[40] Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
Rodriguez-Torres, Maribel
Stoehr, Albrecht
Gane, Edward J.
Serfaty, Lawrence
Lawitz, Eric
Zhou, Amy
Bourque, Michael
Bhanja, Sanhita
Strizki, Julie
Barnard, Richard J. O.
Hwang, Peggy M. T.
DiNubile, Mark J.
Mobashery, Niloufar
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (06) : 1029 - +

← 1 2 3 4 5 →